0001209191-23-057712.txt : 20231207
0001209191-23-057712.hdr.sgml : 20231207
20231207160355
ACCESSION NUMBER: 0001209191-23-057712
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231205
FILED AS OF DATE: 20231207
DATE AS OF CHANGE: 20231207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Conner Edward R.
CENTRAL INDEX KEY: 0001691265
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41498
FILM NUMBER: 231472351
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD.
STREET 2: POINT RICHMOND TECH CENTER
CITY: RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Third Harmonic Bio, Inc.
CENTRAL INDEX KEY: 0001923840
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 834553503
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1700 MONTGOMERY STREET
STREET 2: SUITE 210
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
BUSINESS PHONE: 2097272457
MAIL ADDRESS:
STREET 1: 1700 MONTGOMERY STREET
STREET 2: SUITE 210
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-05
0
0001923840
Third Harmonic Bio, Inc.
THRD
0001691265
Conner Edward R.
1700 MONTGOMERY STREET
SUITE 210
SAN FRANCISCO
CA
94111
0
1
0
0
Chief Medical Officer
1
Common Stock
2023-12-05
4
M
0
4790
4.20
A
4790
D
Common Stock
2023-12-05
4
S
0
4790
10.0339
D
0
D
Employee Option Grant (right to buy)
4.20
2023-12-05
4
M
0
4790
0.00
A
2032-07-27
Common Stock
4790
378498
D
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated May 15, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
25% of the total shares vested on June 6, 2023, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
/s/ Julie Person, Attorney-in-Fact
2023-12-07